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IgG molecules exert both pro- and antiinflammatory effector functions based on the composition of the fragment crystallizable
(Fc) domain glycan. Sialylated IgG Fc domains have antiinflammatory properties that are attributed to their ability to increase
the activation threshold of innate effector cells to immune complexes by stimulating the upregulation of the inhibitory Fcγ
receptor IIB (FcγRIIB). Here, we report that IgG Fc sialylation of human monoclonal IgG1 molecules impairs their efficacy to
induce complement-mediated cytotoxicity (CDC). Fc sialylation of a CD20-targeting antibody had no impact on antibodydependent cellular cytotoxicity and did not change the affinity of the antibody for activating Fcγ receptors. In contrast, the
presence of sialic acid abrogated the increased binding of C1q to Fc-galactosylated IgG1 and resulted in decreased levels of C3b
deposition on the cell surface. Similar to monoclonal antibodies, sialic acid inhibited the increased C1q binding to galactosylated
Fc fragments in human polyclonal IgG. In sera derived from patients with chronic inflammatory demyelinating polyneuropathy,
an autoimmune disease of the peripheral nervous system in which humoral immune responses mediate tissue damage,
induction of IgG Fc sialylation was associated with clinical disease remission. Thus, impairment of CDC represents an FcγRindependent mechanism by which Fc-sialylated glycovariants might limit proinflammatory IgG effector functions.

Introduction

IgG molecules can trigger both pro- and antiinflammatory
responses mediated by their fragment crystallizable domain
(Fc). Proinflammatory pathways include the activation of innate
immune effector cells via cellular receptors specific for the antibody constant region (Fcγ receptors, herein referred to as FcγRs)
and the activation of the complement system. Activation of the
classical complement pathway via C1q binding to human IgG1
and IgG3 molecules generates proinflammatory anaphylotoxins C3a and C5a, which can trigger innate immune effector cell
recruitment, and deposition of C3b on target cells enables their
recognition through C3b receptors expressed on phagocytic, antigen-presenting cells (1, 2). Compared with the aforementioned
effector functions that establish and maintain tissue inflammation, our understanding how IgG contributes to the resolution of
inflammation is still vague.
Recent studies provided evidence that carbohydrates in the
sugar moiety attached to the IgG Fc domain are essential for IgG
functionality and its antiinflammatory capacity (3). IgG Fc contains a
single, highly conserved asparagine 297 (N297) glycosylation site in
each of the 2 CH2 domains. The glycans are buried within the hydrophobic core between the 2 heavy chains and influence Fc structure
(4, 5). The biantennary core glycan structure, which is composed
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of 2 N-acetylglucosamines (GlcNAc) and 3 mannose residues, can
be further decorated with fucose, bisecting GlcNAc and terminal
GlcNAc, galactose, and sialic acid. Genetic or enzymatic removal of
this sugar moiety results in a loss of both pro- and antiinflammatory
activities of IgG (1, 6).
Antiinflammatory activities of IgG have been associated with
the presence of sialic acid, based on observations that patients
with autoimmune diseases such as rheumatoid arthritis show
decreased levels of IgG Fc sialylation (7–9) and the finding that
the antiinflammatory activity of i.v. immunoglobulins (IVIG)
in various murine models of antibody-mediated autoimmune
diseases could be recapitulated using sialylated Fc fragments
derived from IVIG or a human IgG1 recombinant antibody at a
30-fold lower dose than IVIG (10–12).
The antiinflammatory activity of sialylated IgG Fc has
been attributed to its ability to induce the production of IL-33
by myeloid regulatory cells upon binding to the lectin DC–specific ICAM-3–grabbing nonintegrin receptor DC-SIGN, which,
in turn, induces expansion of IL-4–producing basophils that
promote increased expression of the inhibitory Fcγ receptor
FcγRIIB, thereby increasing the activation threshold of innate
effector cells to immune complexes (13). More recently, it has
been demonstrated that IgG Fc sialylation acts as a negative regulator of B cell proliferation independent of FcγRIIB expression
(14, 15). Here, we show that Fc sialylation inhibits immediate
proinflammatory IgG effector functions through impairment of
complement-mediated cytotoxicity.
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Figure 1. Characterization of unmodified and tetra-Fc–sialylated RTX. (A) Immunoblotting of RTX and tetra-Fc–sialylated RTX using lectins specific for
individual glycans (mannose: LCA; terminal galactose: ECL; sialic acid: SNA). (B) Liquid chromatography-mass spectrometry (LC/MS) analysis of the tetraFc–sialylated RTX after reduction to separate the light chain and heavy chain.

Results

IgG Fc sialylation impairs complement-dependent cytotoxicity.
Rituximab (RTX) is a chimeric mouse-human IgG1 monoclonal
antibody that targets the CD20 antigen, which is expressed on B
lymphocytes. RTX depletes B cells through a combination of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (16). The major Fc glycans of
commercial RTX are core-fucosylated biantennary complex–type
oligosaccharides carrying 0–2 galactose moieties buy lacking
sialic acid (refs. 17, 18, and Figure 1A). A homogeneous, tetra-Fc–
sialylated glycoform (G2SA2) of RTX — i.e., carrying 4 sialic acids
per Fc fragment (2 sialic acids per Fc glycan [Figure 1A and Supplemental Figure 1; supplemental material available online with this
article; doi:10.1172/JCI82695DS1]) — was prepared by the chemoenzymatic glycosylation remodeling of commercial RTX (17), and
the purity and identity of the fully sialylated RTX were confirmed
by electron spray ionization-liquid chromatography/mass spectrometry (ESI-LC/MS) analysis of the light chain and heavy chain
of the product (Figure 1B). We employed these 2 glycoforms— i.e.,
commercial RTX not carrying sialic acid versus tetra-Fc–sialylated
RTX — to determine whether IgG Fc sialylation impacts the efficacy of CD20-targeted B cell depletion.
Incubation of natural killer cells (NK cells) with either the
unmodified or tetra-Fc–sialylated antibody resulted in efficient
lysis of autologous B cells, and the depleting efficacy was similar between the 2 glycoforms (Figure 2A). In addition, both glycoforms exhibited similar binding affinities for the activating Fc
receptors FcγRIIIA-158F and FcγRIIIA-158V, which, upon ligation, mediate ADCC (Figure 2B). Binding affinities of both glycoforms were also similar for FcγRI and FcγRIIA (Supplemental Figure 1). In stark contrast, tetra-Fc–sialylated RTX was less efficient
in inducing CDC in CD20+ Burkitt’s lymphoma Raji and Ramos
cells (Figure 2C). An alternative approach to achieve Fc sialylation
is to react an Fc glycan containing substrate molecule with β1,4
galactosyltransferase-1 (β1,4GalT) and α2,6-sialyltransferase
(ST6Gal1) enzymes in the presence of the corresponding sugar
nucleotide substrates, which results in enrichment of mono- and
bisialylated species (Supplemental Figure 2 and refs. 11, 19, 20).
As shown in Figure 2D, enzymatic enrichment of RTX for sialylated glycoforms also resulted in decreased efficacy to induce CDC.

To determine whether the effect of Fc sialylation on CDC is RTX
specific, we additionally enriched a monoclonal humanized
IgG1 antibody recognizing myelin oligodendrocyte glycoprotein
(MOG) and lacking Fc sialylation (hu8-18C5) (21) for sialylated
species by β1,4GalT and ST6Gal1 treatment. CDC was assessed
with an oligodendroglial cell line (MO3.13) transduced to express
human full-length MOG (Figure 3 and ref. 22). Similar to RTX,
sialylated glycoforms of the MOG-specific hu8-18C5 antibody
were less efficient in inducing CDC compared with their nonsialic acid-carrying counterparts (Figure 2D). The impaired efficacy
of sialylated IgG to induce CDC was not reflected by decreased
antigen-binding affinities (Figure 3, C and D). These data indicate
that IgG Fc sialylation impairs CDC independently from Fc receptor binding and antigen specificity.
Fc sialylation neutralizes increased C1q binding of Fc-galactosylated IgG. The classical complement pathway is triggered by
binding of C1q to the Fc domain in antibody/antigen complexes,
leading to autoactivation of the C1 complex (comprising C1q, C1r,
and C1s) and activation of complement by cleavage of C4 and C2.
The resulting C4bC2a convertase cleaves C3, causing the covalent
coupling of C3b to reactive surfaces such as the cell membrane,
which culminates in the formation of the membrane attack complex and lysis of the target cell (23).
The binding affinity of C1q for murine IgG has been shown to
be reduced upon the removal of galactose from the IgG Fc–linked
glycan (24). To investigate the mechanism by which Fc sialylation
impacts CDC, we first determined binding affinities and kinetics of
unmodified and tetra-Fc–sialylated RTX with C1q by surface plasmon resonance (SPR) analysis. Compared with unmodified IgG,
the rate of complex formation was lower for tetra-Fc–sialylated IgG
(kon = 1.6 compared with 3.9/107 [ms]–1) while the rate of dissociation
was higher (koff = 0.22 compared with 0.15/s–1), resulting in a 3.7-fold
increased kD for tetra-Fc–sialylated IgG (kD C1q:tetra-Fc–sialylated IgG = 14;
kD C1q:unmodified IgG = 3.8) (Figure 4). Next, we generated galactosylated,
galactosylated and sialylated, and degalactosylated Fc glycovariants of RTX and hu8-18C5 (Figure 5, A and D, and Supplemental
Figure 2) and tested them for their ability to induce cell-associated
complement activation. Both antibodies contain the Fc-glycosylation site at N297 but lack additional fragment antigen binding
(Fab) glycosylation sites (Supplemental Figure 3).
jci.org   Volume 125   Number 11   November 2015
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Figure 2. IgG Fc sialylation impairs complement-dependent but not cell-mediated cytotoxicity. (A) RTX and tetra-Fc–sialylated RTX mediated lysis of B cells
(targets) by autologous NK cells (effectors). Representative experiment and quantification of 3 independent experiments. Statistics were performed by t test.
(B) Binding of RTX and tetra-Fc–sialylated RTX to CHO cells either untransfected or transfected with the low-affinity (158F) or high-affinity (158V) variant
of FcγRIIIA. (C) Complement-mediated lysis of the CD20+ Raji cells. Representative experiment and quantification of EC50 of 3 independent experiments.
Statistics were performed by t test. (D) Complement-mediated lysis of CD20+ Raji cells (left) or MO3.13 MOG cells (right) with RTX and anti-MOG (hu8-18C5) or
Fc-galactosylated and sialylated variants of the antibodies, representative of 3 independent experiments. 158F, Phenylalanine 158; 158V, Valine 158.

Incubation of target cells expressing the cell-surface antigens
for RTX or hu8-18C5 in the presence of human serum complement
led to rapid binding of C1q (Figure 5). Fc galactosylation of unmodified antibodies resulted in a markedly increased capacity to bind
C1q. Subsequent addition of sialic acid abrogated increased C1q
binding of Fc-galactosylated IgG. Fully tetra-Fc–sialylated RTX
was largely devoid of C1q binding (Figure 5). The capacity of Fc
4162
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sialylation to block C1q binding translated into decreased levels of
C3b deposition to the cell surface (Supplemental Figure 4).
To investigate whether these effects can be transferred to
polyclonal IgG, we purified sialylated Fc from IVIG and obtained
desialylated Fc (i.e., terminally galactosylated Fc) following neuraminidase treatment (Figure 6A). Similar to the monoclonal IgGs
tested, enrichment of terminally galactosylated Fc resulted in
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Figure 3. Cell-surface antigen expression on target cells and antigen binding properties of antibody glycovariants. (A) Raji and Ramos cells were analyzed for CD20 expression by flow cytometry. Gray histograms, unstained cells; open histograms, stained cells. (B) MO3.13 cells lentivirally transduced to
express human MOG were analyzed for MOG expression by flow cytometry. Gray histograms, unstained cells; open histograms, stained cells. CD20+ Raji
cells were incubated with RTX or glycovariants of RTX (C) and MO3.13 MOG cells with hu8-18C5 (anti-MOG) or glycovariants of hu8-18C5 (D) following incubation with a fluorescently labeled anti-Ig antibody and detection of antibody binding by flow cytometry. MFI, median fluorescence intensity.

increased binding of C1q, and the presence of sialic acid abrogated
increased C1q binding of galactosylated Fc fragments (Figure 6B).
These data indicate that Fc sialylation exerts immunoregulatory
functions through inhibition of C1q binding and activation of the
classical complement pathway, leading to reduced complementmediated cytotoxicity.
IgG Fc sialylation is associated with autoimmune disease remission. To address the clinical significance of our findings, we investigated whether IgG Fc sialylation is associated with disease activity in
patients with chronic inflammatory demyelinating polyneuropathy
(CIDP), the most common chronic autoimmune neuropathy (25).
Humoral immune responses are considered to have a crucial role in
mediating peripheral nerve damage in CIDP (26, 27). Complement
component 3d is deposited on the outer surface of Schwann cells and
the compact myelin in biopsies from patients with CIDP (28, 29). Sera
and IgG antibodies from CIDP patients induce peripheral demyelination in host animals (30), can increase the permeability of the bloodnerve barrier, and impair nerve conduction in various models of
peripheral neuropathies (27). Moreover, removal of humoral immune
mediators by plasma exchange is associated with short-term clinical
disease remission and first-line therapy in CIDP (31, 32).
First, we analyzed 19 patients with CIDP who were included in
a randomized placebo-controlled clinical trial testing the efficacy of
i.v. injection of 10% caprylate-chromatography–purified IVIG — 2 g/
kg body weight initially and 1 g/kg body weight every 3 weeks thereafter for 24 weeks — compared with 0.1% albumin (placebo) (32). In

this trial, disease remission was defined as improvement in clinical
disease severity after 24 weeks and was observed in 32 of 59 (54%)
patients treated with IVIG and 12 of 58 (21%) patients who received
placebo (32). We found that patients with clinical disease remission during placebo therapy could be distinguished from those with
stable or worsened disease by the induction of Fc sialylation (Figure
7A). Changes in Fc galactosylation and fucosylation were similar in
patients with disease remission compared with stable or worsened
disease. In patients who received IVIG, we detected an increase of
total IgG serum levels 2 weeks after the last infusion compared with
baseline levels (Supplemental Figure 5A), which precluded profiling
of endogenous IgG in this cohort. We therefore analyzed serum samples from an independent, additional cohort of 33 patients (termed
Marburg cohort) in whom posttreatment samples were taken 3–5
weeks following the last infusion of IVIG (mean ± SD: 4 ± 0.6) and
in which total serum IgG levels after IVIG therapy were unchanged
compared with pretreatment samples (Supplemental Figure 5B). In
this cohort, reduction in clinical disease severity scores upon IVIG
therapy was significantly associated with an induction of IgG Fc
sialylation (r = 0.63, P = 0.0001) (Figure 7B). We consider it unlikely
that we profiled the sialic acid content of the IVIG product used to
treat these patients, since the correlation of Inflammatory Neuropathy Cause and Treatment (INCAT) disease score reduction with
increased IgG Fc sialylation remained significant after exclusion of
3 patients who showed substantially increased IgG levels 3–5 weeks
after IVIG therapy as compared with pretreatment levels (r = 0.57,
jci.org   Volume 125   Number 11   November 2015
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Figure 4. SPR of C1q binding to RTX and tetra-Fc–sialylated RTX. Sensorgrams and results of global fits (table) from SPR measurements.

P = 0.0011). Moreover, Fc-sialylated glycoforms represent only a
minor fraction of glycovariants present in IVIG products (6), and
the increase of total IgG serum levels 2 weeks after the last infusion
in the first cohort of patients in remission was not associated with
an upregulation of Fc sialylation (Supplemental Figure 5C). No significant correlation was observed for IgG Fc galactosylation, fucosylation, and the reduction of disease severity (Figure 7B).
We additionally determined complement activation in patients
with CIDP from whom additional serum samples were available
(Marburg cohort). Levels of soluble terminal complement complex
(TCC, SC5b-9) generated by the assembly of C5b through C9 and
previously shown to correlate with disease activity in patients with
SLE (33) were quantified by ELISA according to the manufacturer’s
recommendation. CIDP patients with high levels of Fc–sialic acid
induction — as defined by at least 2-fold induction of Fc sialylation
— showed significantly lower levels of complement activation following IVIG therapy compared with baseline levels (Figure 7C).
Thus, induction of Fc sialylation is associated with both spontaneous and treatment-induced disease remission, as well as decreased
levels of TCC formation.

Discussion

Complement activation is a potent proinflammatory mechanism
by which IgG antibodies trigger immune responses during infection, and its deregulation causes tissue damage in a wide array of
human inflammatory, degenerative, and autoimmune diseases
(23). Our study shows that the antiinflammatory activities of
sialylated IgG Fc include the impairment of complement-dependent cytotoxicity by reducing the binding affinity of IgG Fc to C1q.
Induction of IgG Fc sialylation is associated with clinical disease
remission in CIDP, an autoimmune disease in which humoral
immune responses are central in mediating tissue damage.
4164
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We profiled total serum IgG Fc glycovariants since no specific
pathogenic autoantibody or single triggering antigen has yet been
identified in CIDP (34). Thus, while our data do not demonstrate
induction of sialylation in specific autoantibodies causing the disease, they indicate that induction of Fc sialylation in CIDP sera is
associated with clinical disease remission.
The observed mechanism of action of Fc sialylation was not
identified in animal models of autoimmune diseases in which
IVIG therapy and Fc sialylation proved to be effective, such as the
K/BxN serum transfer arthritis model and the antiplatelet monoclonal antibody 6A6–mediated model for immune thrombocytopenia (10, 11, 13, 20). However, the aforementioned autoimmune
disease models are largely mediated by IgG-dependent activation
of innate immune effector cells via crosslinking of cellular FcγRs,
whereas IgG-dependent activation of the classical complement
pathway via C1q was shown to be largely dispensable for disease
development (1, 24, 35–49).
The N-glycan resides in the CH2 domain, which is required for
C1q binding (50). For human IgG1, 4 spatially close sites on the surface of the antibody — D270, K322, P329, and P331 — were shown
to constitute the C1q binding epicenter (51). However, most of the
aforementioned sites are conserved in human IgG isotypes that
are deficient in C1q binding; it has therefore been suggested that
the composition of the N-glycan might be critical for the antibodies’ conformation and its ability to bind C1q (51, 52). In line with
this assumption, we observed that presence of terminal galactose
increases binding affinities for C1q and that subsequent addition
of sialic acid inhibited the increased C1q binding. Crystallographic
and biophysical studies on sialylated and asialylated IgG Fc fragments have shown that IgG Fc sialylation disrupts glycan interactions with amino acid residues of the CH2 domain, leading to
significant conformational changes seen in the protein structure
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Figure 5. C1q binding to IgG Fc glycovariants.
(A) Lectin immunoblotting of RTX glycovariants.
(mannose: LCA; terminal galactose: ECL; sialic acid:
SNA). (B) Time-course of C1q binding to CD20+ Raji
cells in the presence or absence of differentially
glycosylated RTX. Mean ± SD of 6 independent
experiments. Median fluorescence intensity
obtained for the unmodified antibody after 60
minutes was set to 100, and the relative signals
were calculated. (C) Quantification of RTX antibody
glycovariant-dependent C1q binding to CD20+ Raji
and Ramos cells after 30 minutes incubation.
Mean ± SD of at least 3 independent experiments.
Statistics were performed by 1-way ANOVA and
Bonferroni post test. (D) Lectin immunoblotting
of hu8-18C5 (anti-MOG) glycovariants. (E) Timecourse of C1q binding to MO3.13 MOG cells in the
presence or absence of differentially glycosylated
variants of hu8-18C5. Mean ± SD of 8 independent experiments. Median fluorescence intensity
obtained for the unmodified antibody after 30
minutes was set to 100 and the relative signals
were calculated. (F) Quantification of hu8-18C5
antibody glycovariant–dependent C1q binding to
MO3.13 MOG cells after 60 minutes. Statistics were
performed by 1-way ANOVA and Bonferroni post
test. (G) Representative flow cytometry stainings
showing C1q binding to the indicated cell type and
antibody after 1 hour incubation.

(53, 54). These data suggest that addition of
sialic acid induces structural changes in IgG
Fc fragments, which translate into reduced
C1q binding and CDC.
Taken together, we identified an FcγRindependent mechanism by which Fcsialylated glycovariants acquire antiinflammatory properties and limit proinflammatory
IgG effector function. This mechanism might
complement immunomodulatory effects of
sialylated IgG associated with upregulation
of the inhibitory FcγRIIB (1, 55) and supports
the development of strategies that target
increased Fc sialylation for the treatment of
human autoimmune diseases (56).

Methods

Patients. Samples and clinical data were collected during a randomized placebo-controlled
trial (ICE trial) testing the efficacy of i.v. injection of 10% caprylate-chromatography purified immunoglobulin (IGIV-C, Gamunex, Grifols Therapeutics Inc.) in patients with CIDP
(32). Patients included in the ICE trial did not
receive IVIG treatment in the 3 months before
study entry. An additional cohort of patients
was recruited between 2010 and 2013 at the
Department of Neurology, University of Marburg, Germany (Supplemental Table 1). All
patients fulfilled the European Federation of
Neurological Societies/Peripheral Nerve Socijci.org   Volume 125   Number 11   November 2015
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Figure 6. C1q binding to human polyclonal IgG Fc glycovariants. (A) Lectin
immunoblotting of Fc purified from
human polyclonal IgG and enriched for
sialylated Fc or desialylated (mannose:
LCA; terminal galactose: ECL; sialic acid:
SNA). (B) C1q binding to polyclonal IgG Fc
glycovariants measured by ELISA. Mean
and ± SEM of 3 independent experiments. C1q binding was normalized to
unmodified Fc at 10% serum. Individual
curves were compared with Fc using
2-way ANOVA and Bonferroni post test
comparing Fc and desialylated Fc, or
Fc and sialic acid–enriched Fc (P values
below curve).

ety diagnostic criteria for CIDP. They were prospectively followed
during IVIG therapy using the INCAT score to monitor clinical treatment response. Patients did not receive IVIG therapy before study
entry. Serum samples were collected at each visit.
Buffers and reagents. RPMI-1640, DMEM, penicillin-streptomycin (P/S), pooled human serum, TO-PRO-3 Stain, LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit, LIVE/DEAD Fixable Aqua Dead
Cell Stain Kit, 1-Step Ultra TMB-ELISA Substrate Solution and
CaptureSelect IgG-CH1 PRO Affinity Matrix were purchased from
Invitrogen. Recombinant human IL-2 was purchased from PeproTech. PKH26 Red Fluorescent Cell Linker Kit was purchased from
Sigma-Aldrich. Ficoll-Paque was purchased from GE Healthcare.
Accutase was purchased from StemCell Technologies Inc. MACS
NK Cell Isolation Kit-II (negative selection) and B Cell Isolation
Kit (CD19+ selection) were purchased from Miltenyi Biotec. Human
serum complement, C5 depleted human serum, MicroVue SC5b-9
Plus ELISA, and recombinant human C1q were purchased from
TECOmedical Group. EZ-Link NHS-PEG12-Biotin was purchased
from Thermo Scientific. Papain and Nutridoma-SP were purchased
from Roche Applied Science. HiLoad 16/60 Superdex 200 column,
HiTrap Protein G HP Columns, StrepTrap HP Columns, HisTrap HP
columns, and Protein G Sepharose 4 Fast Flow were purchased from
GE Healthcare. Ceramic Fluoroapatite (CFT-II, 40 μM) was purchased from Bio-Rad. Biotinylated lectins (Lens culinaris agglutinin
[LCA], Sambucus nigra agglutinin [SNA], Erythrina cristagalli lectin
[ECL], and Aleuria aurantia lectin [AAL]) and SNA-Agarose were
purchased from Vector Laboratories. Neuraminidase was purchased
from New England Biolabs Inc. UDP-Galactose, CMP-Sialic Acid,
β1,4-Galactosidase were purchased from Merck. StarGate cloning
and expression system was purchased from IBA. CMD500L sensor
chip was from Xantec.
Antibodies and streptavidin. RTX (MabThera, catalog 10129436)
was purchased from Roche Applied Science. Monoclonal mouse
anti–human C1q (catalog A201), biotinylated anti–human C1q (catalog A700), and anti–human-C3c (catalog A701) were purchased from
TECOmedical Group. Anti–human IgG Fc-HRP (catalog A0170) was
purchased from Sigma-Aldrich. Anti–CD20-PE-Cy7 (clone 2H7) was
4166
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purchased from eBioscience. Polyclonal rabbit anti–mouse IgG (H+L)Alexa Fluor 488 (catalog A-11059) was purchased from Invitrogen.
Streptavidin-FITC (catalog 405202) and streptavidin-PE (catalog
405204) were purchased from BioLegend.
CDC assay. Raji or Ramos cells expressing the target antigen of RTX (CD20; Figure 3A) were used to assess RTX-mediated
CDC. Therefore, 7 × 104 cells were placed in a humidified incubator at 37°C and 5% CO2 in RPMI-1640 containing P/S (50 U/ml) in
96-well V-bottom plates in the presence or absence of RTX or glycovariants of it. After 30 minutes, human serum complement was
added to a final concentration of 5%, and the incubation was continued for 12 hours. For hu8-18C5–mediated CDC, 2 × 104 MO3.13
MOG cells were seeded in 96-well flat-bottom plates in DMEM plus
10% FCS. On the next day, the medium was removed, and DMEM
containing 15% serum complement with or without hu8-18C5 or a
glycovariant of it was added following incubation for 4 hours in a
humidified incubator at 37°C and 5% CO2. For cell-death assessment, TO-PRO-3 stain was added to a final concentration of 200
nM. Cells were acquired using BD FACS Canto-II (BD Biosciences)
and analyzed with FlowJo (Tree Star).
ADCC assay. ADCC assay was performed as previously described
(57). Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats using Ficoll-Paque. NK cells were negatively
selected using MACS NK cell isolation kit, and B cells were positively
selected using MACS CD19+ selection kit. Both cells were cultured
overnight in RPMI supplemented with P/S (50 U/ml) and 5% heatinactivated pooled human serum in 24-well plates at 5 × 106 cells per
well. NK cell medium was additionally supplemented with 100 IU
IL-2. On the next day, B cells were stained with PKH26 according to
the manufacturer’s recommendation. B cells (1 × 104) were incubated
in the presence of autologous NK cells (1 × 103–1 × 105) and RTX (0.1
μg/ml–1 ng/ml) in RPMI supplemented with P/S (50 U/ml), 5% heatinactivated pooled human serum, and 100 IU IL-2 in 96-well roundbottom plates for 18 hours in a humidified incubator at 37°C and 5%
CO2. For cell-death assessment, TO-PRO-3 stain was added to a final
concentration of 200 nM. Cells were acquired using BD FACS Canto-II and analyzed with FlowJo.
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Figure 7. Induction of IgG Fc sialylation is associated with disease remission in CIDP. (A) Serum IgG Fc glycan composition of CIDP patients analyzed
by lectin blotting. Relative IgG Fc glycan abundance of CIDP patients before and after a 24-week observation period. Patients undergoing spontaneous
disease remission are compared with those with stable or worsening disease (no remission). Statistics were performed by Mann-Whitney U test. (B) IgG
Fc glycan composition analysis of CIDP patients (Marburg patient cohort) before and 3–5 weeks after receiving the last IVIG injection. Fold changes in
glycan composition are compared with disease activity changes reflected by the INCAT score. Statistics were performed by Spearman test. (C) Complement
activation as defined by serum levels of the TCC (SC5b-9) quantified by ELISA before and 3–5 weeks after IVIG therapy (Marburg patient cohort). Statistics
were performed by Mann–Whitney U test.

FcγR binding assay. RTX and tetra-Fc–sialylated RTX were biotinylated using EZ-Link NHS-PEG12-Biotin according to the manufacturer’s recommendations. CHO cells (1 × 105) stably expressing none
or 1 of the human FcγRs (58), a gift from Falk Nimmerjahn (Department of Biology, University of Erlangen-Nuremberg, Germany), were
incubated for 30 minutes on ice in the presence of RTX or tetra-Fc–
sialylated RTX. Cells were washed twice with PBS and incubated for
30 minutes with streptavidin-FITC for detection of binding and LIVE/
DEAD Fixable Near-IR Dead Cell Stain Kit for dead cell exclusion.
After washing twice with PBS, cells were acquired using BD FACS
Canto-II and analyzed with FlowJo.
Purification of Fc, desialylated Fc, and sialic acid–enriched Fc from
polyclonal IgG. IVIG (Pivigen, CSL Behring) was used as source of
human IgG. IgG (550 mg) was incubated in 0.02 M EDTA and 0.02
M L-cysteine in PBS at pH 6.5 with 0.8 mg papain for 2 hours at 25°C.
Uncut IgG and papain were separated by size exclusion with a HiLoad
16/60 Superdex 200 column and GE Aekta purifier. The fraction containing the Fc and Fab fragments was concentrated and dialyzed to
5 mM Na-phosphate buffer pH 7.1. Fab and Fc were separated using
a Ceramic Fluoroapatite column (CFT-II, 40 μm), which binds Fab
but not Fc. For purification of sialic acid–enriched Fc, Fc was dialyzed
to TBS and CaCl2 was added to a final concentration of 0.1 M. Sialic
acid–enriched Fc was purified from 40 mg Fc by binding to 4 ml SNAAgarose and elution with 0.5 M lactose in TBS as previously described
(11). For neuraminidase treatment, Fc was dialyzed to 50 mM sodium
citrate pH 6 and incubated with 1 unit neuraminidase per μg Fc for
48 hours at 37°C. Neuraminidase was removed using Protein-G sepharose 4 Fast Flow. For further purification, Fc, desialylated Fc, and
sialic acid–enriched Fc were cleared from residual Fab using a CaptureSelect IgG-CH1 pro affinity matrix and reapplied to a HiLoad
16/60 Superdex 200 column.
Purification of hu8-18C5 antibody. The hu8-18C5 antibody has
been generated by cloning of the 8-18C5 hybridoma–derived Igh
and Igk variable–region sequences into human IgG1 heavy-chain
and κ light chain expression vectors as previously described (21).

hu8-18C5 was purified by cotransfecting the calcium phosphate
precipitated expression vectors in HKB-11 cells. After 12 hours,
the medium was exchanged to DMEM containing P/S (50 U/ml)
and 1% Nutridoma-SP. The culture supernatant was harvested 4
days later, and antibodies were purified using HiTrap Protein G HP
columns according to the manufacturer’s instructions using GE
Aekta prime plus.
Purification of recombinant glycosyltransferases. For purification
of sialyl- and galactosyl-transferases, cDNA of bovine β1,4GalT and
human ST6Gal1 was cloned into pCSG-IBA-144 expression vectors
using the StarGate cloning system (IBA) according to the manufacturer’s instructions. This yields plasmids encoding for proteins containing an N-terminal Twin-Strep-tag and a C-terminal Hexahistidinetag. 293T cells were cultured under standard cell-culture conditions in
DMEM containing 10% FCS and P/S (50 U/ml) and transfected with
calcium-phosphate precipitated plasmids encoding either β1,4GalT or
ST6Gal1. After 12 hours, the medium was replaced with fresh DMEM
containing 10% FCS and P/S (50 U/ml), and cells were cultured for
another 3 days. The cell supernatant was harvested, and the proteins
were purified by immobilized metal ion affinity chromatography (HisTrap HP columns) and subsequently Strep-Tactin affinity chromatography (Strep-Trap HP columns) according to the manufacturer’s
instructions using GE Aekta prime plus.
Generation of antibody glycovariants. Tetra-Fc–sialylated RTX
was generated by chemoenzymatic glycoengineering as previously
described (17) with adequate modifications. Briefly, commercial
RTX (8 mg) was incubated with EndoS WT (25 μg) at 37°C for 1
hour, and the completion of deglycosylation was confirmed by
LC/MS analysis. The deglycosylated antibody was purified using
a HiTrap protein A column, and the eluted fractions were concentrated and buffer exchanged into 1 × PBS pH 7.4. The purified
Fuc-α1,6-GlcNAc-RTX (7 mg) and sialylated complex type oxazoline (3.5 mg) were incubated with EndoS D233Q (175 μg) at 37°C in
100 mM Tris pH 7.4 (500 μl total volume). The reaction progress
was monitored using LC/MS analysis, and complete transfer was
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achieved in 1.5 hours. The tetra-Fc–sialylated RTX was purified
using a HiTrap protein A column and was concentrated and buffer
exchanged into 1 × PBS pH 7.4. LC/MS: heavy chain of RTX with
sialylated complex type glycan, M = 51412 Da; found (m/z), 51412
(deconvolution data). Enzymatic galactosylation and sialylation
were performed as previously described (11, 19). For galactosylation, antibodies were buffer-exchanged to 0.2 mM MES pH 6.5
and incubated for 24 hours at 37°C in the presence of 5 μg β1,4GalT
per mg antibody, 10 mM UDP-galactose, and 20 mM MnCl2. Nongalactosylated antibodies (unmodified) were treated the same
way but without the addition of UDP-galactose and β1,4GalT.
After buffer exchange to 25 mM MOPS 100 mM KCl (pH 7.2), Fcgalactosylated antibodies were Fc-sialylated by the addition of 50
μg ST6Gal1 per mg antibody and CMP-sialic acid at a final concentration of 1.5 mM. The reaction was incubated for 24 hours at
37°C. Nonsialylated antibodies (unmodified and galactosylated)
were treated the same way but without the addition of CMP-sialic
acid and ST6Gal1. All antibodies were buffer-exchanged to TBS.
To enrich for antibodies containing sialic acid, SNA lectin affinity
chromatography was performed as previously described (11). For
degalactosylation, RTX or hu8-18C5 was dialyzed to 50 mM sodium phosphate pH 6.0 and incubated 6 hours at room temperature
and 1 hour at 37°C in the presence of 30 mU β1,4-galactosidase per
mg antibody. Finally, all antibodies were purified using protein-G
sepharose 4 fast flow according to the manufacturer’s instruction,
dialyzed to PBS, and sterilized by 0.2 μM filtration. Acrylamide
gel electrophoresis and silver staining were performed to test antibody integrity and purity, and lectin-blotting was used to confirm
glycan modifications.
C1q binding assay. For C1q binding to Raji or Ramos cells, 2 × 105
cells were seeded in RPMI-1640 containing 1% C5-depleted human
serum in the presence of 10 μg/ml RTX or RTX glycovariants for
5, 15, 30, 60, or 120 minutes in a humidified incubator at 37°C and
5% CO2. For C1q binding to MO3.13 MOG cells, cells were detached
using accutase, and 1 × 105 cells were seeded in DMEM containing
1% C5-depleted serum in the presence of 2.5 μg hu8-18C5 or hu818C5 glycovariants for 5, 15, 30, 60, or 120 minutes in a humidified
incubator at 37°C and 5% CO2. C1q binding was detected by staining on ice with biotinylated anti-C1q for 1 hour. Cells were washed
twice with PBS and incubated on ice with streptavidin-PE and LIVE/
DEAD Fixable Aqua Dead Cell Stain Kit for 25 minutes. After washing twice with PBS, samples were acquired using BD FACS Canto-II
and analyzed with FlowJo.
C3b deposition assay. Raji cells (2 × 105) were seeded in RPMI-1640
containing 1% C5-depleted serum in the presence of 10 μg/ml RTX
or RTX glycovariants for 5, 15, 30, 60, or 120 minutes in a humidified
incubator at 37°C and 5% CO2. For C3 deposition assessment, cells
were stained with biotinylated anti-C3c for 1 hour on ice. Cells were
washed twice with PBS and incubated on ice with streptavidin-PE and
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for 25 minutes. After
washing twice with PBS, samples were acquired using BD FACS Canto-II and analyzed with FlowJo.
C1q binding ELISA. Microtiter plates were coated overnight
at 4°C with 0.5 μg Fc, desialylated Fc, or sialic acid–enriched Fc in
coating buffer (0.05 M sodium carbonate buffer, pH 9). Binding
efficiency to the plate was examined using anti–human IgG Fc-HRP
as the probe. Wells were washed and incubated with human serum
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complement diluted in PBS containing 0.05% Tween20 (PBS-T) and
1% BSA for 2 hours at room temperature. After washing with PBS-T,
wells were incubated for 1 hour with biotinylated anti-C1q, washed
with PBS-T, and incubated for 1 hour with streptavidin-HRP. HRP
activity was quantified using incubation TMB-ELISA substrate and
colorimetric detection at 450 nm.
Serum IgG quantification. Serum samples were taken before the
initiation of the study (baseline) and 24 weeks (ICE trial) or >7 weeks
(Marburg cohort) thereafter; samples were stored at –80°C. Total
serum IgG levels were determined using a commercially available
human IgG ELISA (Immundiagnostik).
Lectin immunoblotting and Fc-linked glycan profiling. Fc-linked glycans were analyzed by lectin immunoblotting using the biotinylated
lectins SNA, ECL, LCA, and AAL (10, 11). Lectin binding was detected
using HRP-labeled streptavidin and quantified by chemiluminescence
using ImageJ. Signal intensities for each glycan (fucose, terminal
galactose, and sialic acid) were normalized to the signal obtained for
the core glycan (mannose).
SC5b-9 ELISA. Complement activation was determined in
patients with CIDP from whom additional serum samples were available (Marburg cohort) using an ELISA detecting serum levels of the
TCC (SC5b-9) according to the manufacturer’s recommendation.
SPR. A Biacore T100 (GE Healthcare) was used for measuring
kinetic data. Antibodies were immobilized on a CMD500L sensor
chip surface via EDC/ NHS (0.4 M/ 0.1 M) surface activation in 10
mM acetate buffer pH 5.5 at 0.1 mg/ml (2,800/2,800 RU for RTX/
tetra-Fc–sialylated RTX) as previously described (59). Dilution series
of C1q (5 nM–20 pM) were injected for 75 seconds at 30 μl/min. Sensograms were analyzed using Biacore Evaluation Software applying
a 1:1 kinetic model.
Statistics. All data represent the mean ± SD. Statistical significance
was defined at a P value of 0.05 or less. All analyses were performed
using Prism software, version 5 (GraphPad Software, Inc.). Specific
statistical tests are listed in figure legends.
Study approval. The IRBs and ethics committees of the University
of Marburg (file reference: 46/00) and all centers that participated
in the ICE trial (32) approved the study. All patients provided written
informed consent.

Acknowledgments

We thank our patients for their continuous cooperation. I.
Quast was supported by a DOC scholarship provided by the
Austrian Academy of Sciences (ÖAW). Christian W. Keller was
supported by a postdoctoral fellowship provided by the German
Research Foundation (DFG). We thank Patrick Weber (Institute
of Experimental Immunology, Laboratory of Neuroinflammation, University of Zürich) for expert technical assistance
and Jens Sobek (Functional Genomics Center, University of
Zürich) for assistance with Biacore measurements. The work
was supported in part by the German Science Foundation (DFG
grant TRR130 to F. Nimmerjahn) and the NIH (NIH grant R01
GM096973 to L.X. Wang).
Address correspondence to: Jan D. Lünemann, Institute of Experimental Immunology, Laboratory of Neuroinflammation, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. Phone: 41.44.635.3710; E-mail: jan.luenemann@uzh.ch.

Downloaded from http://www.jci.org on December 13, 2015. http://dx.doi.org/10.1172/JCI82695

Research article

The Journal of Clinical Investigation  
1. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol.
2013;13(3):176–189.
2. Carroll MC. The role of complement and complement receptors in induction and regulation of
immunity. Annu Rev Immunol. 1998;16:545–568.
3. Dalziel M, Crispin M, Scanlan CN, Zitzmann N,
Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science.
2014;343(6166):1235681.
4. Barb AW, Prestegard JH. NMR analysis demonstrates immunoglobulin G N-glycans are accessible
and dynamic. Nat Chem Biol. 2011;7(3):147–153.
5. Lux A, Nimmerjahn F. Impact of differential
glycosylation on IgG activity. Adv Exp Med Biol.
2011;780:113–124.
6. Arnold JN, Wormald MR, Sim RB, Rudd PM,
Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
7. Parekh RB, et al. Association of rheumatoid
arthritis and primary osteoarthritis with changes
in the glycosylation pattern of total serum IgG.
Nature. 1985;316(6027):452–457.
8. Parekh RB, Roitt IM, Isenberg DA, Dwek RA,
Ansell BM, Rademacher TW. Galactosylation
of IgG associated oligosaccharides: reduction
in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity.
Lancet. 1988;1(8592):966–969.
9. Fokkink WJ, et al. IgG Fc N-glycosylation in
Guillain-Barre syndrome treated with immunoglobulins. J Proteome Res. 2014;13(3):1722–1730.
10. Kaneko Y, Nimmerjahn F, Ravetch JV. Antiinflammatory activity of immunoglobulin
G resulting from Fc sialylation. Science.
2006;313(5787):670–673.
11. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation
of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320(5874):373–376.
12. Anthony RM, Wermeling F, Karlsson MC,
Ravetch JV. Identification of a receptor required
for the anti-inflammatory activity of IVIG. Proc
Natl Acad Sci U S A. 2008;105(50):19571–19578.
13. Anthony RM, Kobayashi T, Wermeling F, Ravetch
JV. Intravenous gammaglobulin suppresses
inflammation through a novel T(H)2 pathway.
Nature. 2011;475(7354):110–113.
14. Oefner CM, et al. Tolerance induction with T
cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol.
2012;129(6):1647–1655.
15. Hess C, et al. T cell-independent B cell activation
induces immunosuppressive sialylated IgG antibodies. J Clin Invest. 2013;123(9):3788–3796.
16. Glennie MJ, French RR, Cragg MS, Taylor RP.
Mechanisms of killing by anti-CD20 monoclonal
antibodies. Mol Immunol. 2007;44(16):3823–3837.
17. Huang W, Giddens J, Fan SQ, Toonstra C, Wang
LX. Chemoenzymatic glycoengineering of intact
IgG antibodies for gain of functions. J Am Chem
Soc. 2012;134(29):12308–12318.
18. Iida S, et al. Nonfucosylated therapeutic IgG1
antibody can evade the inhibitory effect
of serum immunoglobulin G on antibodydependent cellular cytotoxicity through its high

binding to FcgammaRIIIa. Clin Cancer Res.
2006;12(9):2879–2887.
19. Barb AW, Brady EK, Prestegard JH. Branchspecific sialylation of IgG Fc glycans by ST6Gal-I.
Biochemistry. 2009;48(41):9705–9707.
20. Washburn N, et al. Controlled tetra-Fc sialylation
of IVIg results in a drug candidate with consistent
enhanced anti-inflammatory activity. Proc Natl
Acad Sci U S A. 2015;112(11):E1297–E1306.
21. Kuenzle S, et al. Pathogen specificity and autoimmunity are distinct features of antigen-driven
immune responses in neuroborreliosis. Infect
Immun. 2007;75(8):3842–3847.
22. Dale RC, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte
cytoskeleton. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e12.
23. Holers VM. Complement and its receptors: new
insights into human disease. Annu Rev Immunol.
2014;32:433–459.
24. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc
receptors for in vivo activity. Proc Natl Acad Sci
U S A. 2007;104(20):8433–8437.
25. Koller H, Kieseier BC, Jander S, Hartung HP.
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–1356.
26. Tackenberg B, et al. Classifications and treatment responses in chronic immune-mediated
demyelinating polyneuropathy. Neurology.
2007;68(19):1622–1629.
27. Meyer zu Horste G, Hartung HP, Kieseier
BC. From bench to bedside — experimental
rationale for immune-specific therapies in the
inflamed peripheral nerve. Nat Clin Pract Neurol.
2007;3(4):198–211.
28. Dalakas MC, Engel WK. Immunoglobulin and
complement deposits in nerves of patients with
chronic relapsing polyneuropathy. Arch Neurol.
1980;37(10):637–640.
29. Hays AP, Lee SS, Latov N. Immune reactive C3d
on the surface of myelin sheaths in neuropathy.
J Neuroimmunol. 1988;18(3):231–244.
30. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD.
Passive transfer of demyelination by serum
or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol.
2000;47(6):765–775.
31. Dalakas MC. Mechanisms of action of IVIg and
therapeutic considerations in the treatment of
acute and chronic demyelinating neuropathies.
Neurology. 2002;59(12 suppl 6):S13–S21.
32. Hughes RA, et al. Intravenous immune globulin
(10% caprylate-chromatography purified) for the
treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol.
2008;7(2):136–144.
33. Mollnes TE, et al. Complement activation in
patients with systemic lupus erythematosus
without nephritis. Rheumatology (Oxford).
1999;38(10):933–940.
34. Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev
Neurol. 2011;7(9):507–517.
35. Baudino L, et al. Differential contribution of
three activating IgG Fc receptors (FcγRI, FcγRIII,
and FcγRIV) to IgG2a- and IgG2b-induced auto-

immune hemolytic anemia in mice. J Immunol.
2008;180(3):1948–1953.
36. Beers SA, et al. Antigenic modulation limits the
efficacy of anti-CD20 antibodies: implications for
antibody selection. Blood. 2010;115(25):5191–5201.
37. Biburger M, et al. Monocyte subsets responsible
for immunoglobulin G-dependent effector functions in vivo. Immunity. 2011;35(6):932–944.
38. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3(1):21–26.
39. Fossati-Jimack L, et al. Markedly different
pathogenicity of four immunoglobulin G isotypeswitch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo
with the low-affinity Fcgamma receptor III. J Exp
Med. 2000;191(8):1293–1302.
40. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F,
Tedder TF. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte
depletion during CD20 immunotherapy. J Exp
Med. 2006;203(3):743–753.
41. Hogarth PM. Fc receptors are major mediators of
antibody based inflammation in autoimmunity.
Curr Opin Immunol. 2002;14(6):798–802.
42. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch
JV. Pathology and protection in nephrotoxic
nephritis is determined by selective engagement of specific Fc receptors. J Exp Med.
2006;203(3):789–797.
43. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch
JV. FcgammaRIV: a novel FcR with distinct IgG
subclass specificity. Immunity. 2005;23(1):41–51.
44. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor
binding. Science. 2005;310(5753):1510–1512.
45. Ravetch JV, Clynes RA. Divergent roles for Fc
receptors and complement in vivo. Annu Rev
Immunol. 1998;16:421–432.
46. Sylvestre D, Clynes R, Ma M, Warren H, Carroll
MC, Ravetch JV. Immunoglobulin G-mediated
inflammatory responses develop normally
in complement-deficient mice. J Exp Med.
1996;184(6):2385–2392.
47. Sylvestre DL, Ravetch JV. Fc receptors initiate
the Arthus reaction: redefining the inflammatory
cascade. Science. 1994;265(5175):1095–1098.
48. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV.
FcR gamma chain deletion results in pleiotrophic
effector cell defects. Cell. 1994;76(3):519–529.
49. Uchida J, et al. The innate mononuclear phagocyte network depletes B lymphocytes through
Fc receptor-dependent mechanisms during
anti-CD20 antibody immunotherapy. J Exp Med.
2004;199(12):1659–1669.
50. Duncan AR, Winter G. The binding site for C1q
on IgG. Nature. 1988;332(6166):738–740.
51. Idusogie EE, et al. Mapping of the C1q binding
site on rituxan, a chimeric antibody with a human
IgG1 Fc. J Immunol. 2000;164(8):4178–4184.
52. Ward ES, Ghetie V. The effector functions of
immunoglobulins: implications for therapy. Ther
Immunol. 1995;2(2):77–94.
53. Sondermann P, Pincetic A, Maamary J, Lammens
K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl
Acad Sci U S A. 2013;110(24):9868–9872.
54. Ahmed AA, et al. Structural characterization of

jci.org   Volume 125   Number 11   November 2015

4169

Downloaded from http://www.jci.org on December 13, 2015. http://dx.doi.org/10.1172/JCI82695

Research article
anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014;426(18):3166–3179.
55. Tackenberg B, et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad
Sci U S A. 2009;106(12):4788–4792.
56. Harre U, et al. Glycosylation of immunoglobulin

4170

The Journal of Clinical Investigation  
G determines osteoclast differentiation and bone
loss. Nat Commun. 2015;6:6651.
57. Lee-MacAry AE, et al. Development of a novel
flow cytometric cell-mediated cytotoxicity assay
using the fluorophores PKH-26 and TO-PRO-3
iodide. J Immunol Methods. 2001;252(1–2):83–92.
58. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact

jci.org   Volume 125   Number 11   November 2015

of immune complex size and glycosylation
on IgG binding to human FcγRs. J Immunol.
2013;190(8):4315–4323.
59. Dall’Acqua WF, Cook KE, Damschroder MM,
Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its
hinge region. J Immunol. 2006;177(2):1129–1138.

